Status:
COMPLETED
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
Lead Sponsor:
University of California, Davis
Conditions:
Asthma
Allergic Rhinitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
Detailed Description
IgE is a key molecule involved in immediate hypersensitivity and plays a major role in the pathogenesis of allergic diseases. Recently, a therapy based on the use of anti-IgE antibody has been develop...
Eligibility Criteria
Inclusion
- Mild or moderate persistent asthma
- Allergic rhinitis
- Atopic dermatitis
Exclusion
- Other lung diseases
- Blood clotting disorder
- Pregnant or lactating women
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 17 2012
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00367016
Start Date
February 1 2004
End Date
October 17 2012
Last Update
July 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Davis Department of Dermatology
Sacramento, California, United States, 95816